PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia

NCT01037556 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myelogenous Leukemia
Acute Lymphocytic Leukemia

Interventions

DRUG: PR104

Sponsor

Proacta, Incorporated